# Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Source: https://onco.cc/trials/nct05147467/  
OnCo record `nct05147467` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of APG2575 in chronic lymphocytic leukaemia, run by Ascentage Pharma Group Inc., now recruiting.

## Summary

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL is a phase 2 interventional study registered as NCT05147467 by Ascentage Pharma Group Inc., with 75 participants planned, started 2021-12-28 and due to reach its primary completion in 2026-12. Interventions recorded: APG2575.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05147467
- Phase: 2
- Setting: A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT05147467: https://clinicaltrials.gov/study/NCT05147467

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05147467.json